BG45700A3 - Метод за получаване на алфа-хетероциклично заместени толунитрили - Google Patents

Метод за получаване на алфа-хетероциклично заместени толунитрили

Info

Publication number
BG45700A3
BG45700A3 BG081514A BG8151487A BG45700A3 BG 45700 A3 BG45700 A3 BG 45700A3 BG 081514 A BG081514 A BG 081514A BG 8151487 A BG8151487 A BG 8151487A BG 45700 A3 BG45700 A3 BG 45700A3
Authority
BG
Bulgaria
Prior art keywords
tolunitrile
heterocyclic substituted
obtaining alpha
alpha
compounds
Prior art date
Application number
BG081514A
Other languages
English (en)
Inventor
Robert Bowman
Ronald Steele
Leslie Browne
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25274596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG45700(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BG45700A3 publication Critical patent/BG45700A3/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Indole Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Алфа-хетероциклично заместените толунитрили намират приложение в медицината като инхибитори на ароматезата.съединенията се получават при кондензация на горните съединения,в които r долу 1 и r долу 2 означават водород, със съответни съединения осигуряващи тези заместители. 3 претенции
BG081514A 1986-03-07 1987-03-05 Метод за получаване на алфа-хетероциклично заместени толунитрили BG45700A3 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/837,489 US4749713A (en) 1986-03-07 1986-03-07 Alpha-heterocycle substituted tolunitriles

Publications (1)

Publication Number Publication Date
BG45700A3 true BG45700A3 (bg) 1989-07-14

Family

ID=25274596

Family Applications (4)

Application Number Title Priority Date Filing Date
BG081515A BG45701A3 (bg) 1986-03-07 1987-03-05 Метод за получаване на алфа-хетероциклично заместени толунитрили
BG078756A BG46598A3 (bg) 1986-03-07 1987-03-05 Метод за получаване на алфа-хетероциклично заместени толунитрили
BG081514A BG45700A3 (bg) 1986-03-07 1987-03-05 Метод за получаване на алфа-хетероциклично заместени толунитрили
BG098212A BG61204B2 (bg) 1986-03-07 1993-11-11 Алфа-хетероциклени заместени толунитрили

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BG081515A BG45701A3 (bg) 1986-03-07 1987-03-05 Метод за получаване на алфа-хетероциклично заместени толунитрили
BG078756A BG46598A3 (bg) 1986-03-07 1987-03-05 Метод за получаване на алфа-хетероциклично заместени толунитрили

Family Applications After (1)

Application Number Title Priority Date Filing Date
BG098212A BG61204B2 (bg) 1986-03-07 1993-11-11 Алфа-хетероциклени заместени толунитрили

Country Status (36)

Country Link
US (1) US4749713A (bg)
EP (1) EP0236940B3 (bg)
JP (1) JPH0755930B2 (bg)
KR (1) KR910000482B1 (bg)
AT (1) ATE94873T1 (bg)
BG (4) BG45701A3 (bg)
CA (1) CA1316928C (bg)
CY (1) CY1905A (bg)
CZ (3) CZ279027B6 (bg)
DD (1) DD264432A5 (bg)
DE (2) DE3787480T2 (bg)
DK (1) DK172190B1 (bg)
DZ (1) DZ1055A1 (bg)
ES (1) ES2059317T3 (bg)
FI (1) FI91857C (bg)
HK (1) HK50296A (bg)
HU (1) HU202843B (bg)
IE (1) IE61101B1 (bg)
IL (1) IL81746A (bg)
LU (1) LU90128I2 (bg)
LV (1) LV5769B4 (bg)
MA (1) MA20888A1 (bg)
MC (1) MC1805A1 (bg)
MT (1) MTP998B (bg)
MX (1) MX5496A (bg)
MY (1) MY102428A (bg)
NL (1) NL970011I2 (bg)
NO (2) NO170277C (bg)
PH (1) PH24159A (bg)
PL (2) PL152025B1 (bg)
PT (1) PT84410B (bg)
RO (2) RO101533B1 (bg)
SK (3) SK736787A3 (bg)
SU (3) SU1470184A3 (bg)
TN (1) TNSN87033A1 (bg)
ZA (1) ZA871637B (bg)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112845A (en) * 1986-03-07 1992-05-12 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US5352795A (en) * 1986-03-07 1994-10-04 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
GB8714013D0 (en) * 1987-06-16 1987-07-22 Ici Plc (substituted-aralkyl)heterocyclic compounds
DE3811574A1 (de) * 1988-03-31 1989-10-19 Schering Ag N-substituierte imidazole, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE59010171D1 (de) * 1989-07-14 1996-04-11 Ciba Geigy Ag Substituierte Benzonitrile
DE3926365A1 (de) * 1989-08-04 1991-02-07 Schering Ag Cycloalkylenazole, verfahren zu deren herstellung, pharmazeutische praeparate, die diese enthalten sowie ihre verwendung zur herstellung von arzneimitteln
JP2602456B2 (ja) * 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
EP0457716A1 (de) * 1990-04-20 1991-11-21 Ciba-Geigy Ag Naphthalinderivate
DE4039559A1 (de) * 1990-12-07 1992-06-11 Schering Ag Funktionalisierte vinylazole, verfahren zu deren herstellung, pharmazeutische praeparate die diese vinylazole enthalten sowie deren verwendung zur herstellung von arzneimitteln
TW210334B (bg) * 1990-12-12 1993-08-01 Ciba Geigy Ag
CH683151A5 (de) * 1991-04-24 1994-01-31 Ciba Geigy Ag Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus.
DE4120107A1 (de) * 1991-06-14 1992-12-17 Schering Ag Bicyclisch substituierte vinylimidazole, -triazole und -tetrazole
EP0641785B1 (en) 1991-09-02 1999-10-27 Yamanouchi Pharmaceutical Co. Ltd. Triazolylated tertiary amine compound or salt thereof
US5223539A (en) * 1991-11-22 1993-06-29 G. D. Searle & Co. N,n-di-alkyl(phenoxy)benzamide derivatives
AU5285593A (en) * 1992-10-21 1994-05-09 Sankyo Company Limited Azole compound
GB2273704B (en) * 1992-12-16 1997-01-22 Orion Yhtymae Oy Triazolyl diaryl selective aromatase inhibiting compounds
US5426196A (en) * 1993-12-22 1995-06-20 Glaxo Inc. Synthesis of diaryl methanes
WO1997027852A1 (en) * 1996-01-30 1997-08-07 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000505797A (ja) * 1996-01-30 2000-05-16 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
EP0891360A4 (en) * 1996-04-03 2002-05-15 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
CA2249615A1 (en) * 1996-04-03 1997-10-09 Robert Gomez Inhibitors of farnesyl-protein transferase
US6063930A (en) * 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US6080870A (en) * 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
AU2002342335B2 (en) 2001-05-16 2006-02-02 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
AU2002366587A1 (en) * 2001-12-11 2003-06-23 Emory University Bis(cyanophenyl)methyl-triazole for use in prevention of breast cancer
DE60309887T2 (de) * 2002-07-30 2007-05-16 Novartis Ag Kombination von einem aromatasehemmer mit einem bisphosphonat
GB0217636D0 (en) * 2002-07-30 2002-09-11 Novartis Ag Organic compounds
JP2004196795A (ja) * 2002-12-16 2004-07-15 Wyeth 外部寄生虫駆除剤としてのｎ−フェニル−３−シクロプロピルピラゾール−４−カルボニトリル
AU2003282380A1 (en) * 2003-11-14 2004-06-06 ADIBHATLA, KALI,SATYA, Bhujanga,rao A method for the separation of the letrozole precursor 4-1-(1,2,4-triazolyl) methyl benzonitrile from its 1,3,4-triazolyl isomer
RU2365586C2 (ru) * 2003-12-15 2009-08-27 Лаборатуар Терамекс Производные 1-n-фениламино-1н-имидазола и содержащие их фармацевтические композиции
KR100917698B1 (ko) * 2005-07-06 2009-09-21 시코르, 인크. 레트로졸의 제조를 위한 개선된 방법
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US20090082413A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched letrozole
RU2425038C2 (ru) * 2009-11-27 2011-07-27 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") Способ получения 1-[ди(4-цианфенил)метил]-1,2,4-триазола
JP2013525296A (ja) 2010-04-16 2013-06-20 ノバルティス アーゲー 内分泌療法抵抗性乳癌の処置
EP2609087A2 (en) * 2010-08-27 2013-07-03 Generics [UK] Limited Pure intermediate
SI2753312T1 (sl) * 2011-09-08 2017-10-30 Mereo Biopharma 2 Limited Uporaba inhibitorja aromataze za zdravljenje hipogonadizma in sororodnih bolezni
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
EP4772247A2 (en) 2013-08-14 2026-07-08 Novartis AG Combination therapy comprising ribociclib and fulvestrant for the treatment of cancer
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
GB201614179D0 (en) 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
KR20210035211A (ko) 2018-07-23 2021-03-31 에프. 호프만-라 로슈 아게 Pi3k 저해제인 gdc-0077로 암을 치료하는 방법
EP3863618A1 (en) 2018-10-08 2021-08-18 F. Hoffmann-La Roche AG Methods of treating cancer with pi3k alpha inhibitors and metformin
MX2022006566A (es) 2019-12-03 2022-07-01 Genentech Inc Tratamientos conjuntos para tratamiento de cancer de mama.
MX2023006793A (es) 2020-12-11 2023-06-20 Genentech Inc Tratamientos conjuntos para tratamiento de cancer her2.
CN116925001B (zh) * 2023-07-26 2025-09-30 陕西师范大学 一种抗乳腺癌药物来曲唑类似物的合成方法
CN122295128A (zh) 2023-12-05 2026-06-26 基因泰克公司 用于治疗her2癌症的组合疗法
WO2026161536A1 (en) 2025-01-24 2026-07-30 Genentech, Inc. Combination therapies for use in the treatment of breast cancer

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3290281A (en) * 1963-07-18 1966-12-06 Weinstein Julius Photochromic nitrobenzylpyridines
US3397273A (en) * 1966-02-18 1968-08-13 Lilly Co Eli Controlling phytopathogenic fungi on plants with 3-pyridyl methane derivatives
GB1170188A (en) * 1967-09-15 1969-11-12 Bayer Ag N-trityl-imidazoles and salts and uses thereof
DE1670976B2 (de) * 1968-01-29 1976-07-22 N-trityl-imidazole
DE1908991B2 (de) * 1969-02-22 1977-05-26 Bayer Ag, 5090 Leverkusen Alpha, alpha-disubstituierte n- benzylimidazole und deren salze
BR6915465D0 (pt) * 1969-03-07 1973-01-04 Bayer Ag Processo para preparar n-benzimidazois substituidos na posicao alfa por heterociclos penta-membrados com atividade antimicotica
DE2007794A1 (de) * 1970-02-20 1971-09-02 Farbenfabriken Bayer Aktiengesell schaft, 5090 Leverkusen Fungizide Mittel
DE2009020C3 (de) * 1970-02-26 1979-09-13 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von N-(l,l,l-trisubstituierten)-Methylazolen
US3764690A (en) * 1972-03-03 1973-10-09 Bayer Ag Substituted n-benzylimidazoles as antimycotic agents
US3927017A (en) * 1974-06-27 1975-12-16 Janssen Pharmaceutica Nv 1-({62 -Aryl-{62 -R-ethyl)imidazoles
DE2628152C2 (de) * 1976-06-23 1985-03-28 Bayer Ag, 5090 Leverkusen Fungizide und nematizide Mittel
DE2732531A1 (de) * 1977-07-19 1979-02-01 Hoechst Ag Imidazolcarbonsaeuren und deren derivate
DE2735314A1 (de) * 1977-08-05 1979-02-22 Basf Ag Alpha-azolylsulfide und deren derivate
US4431815A (en) * 1977-08-26 1984-02-14 Burroughs Wellcome Co. 1-[3-(2,4-Dichlorophenyl)propyl]imidazole and salts thereof
EP0003732B1 (en) * 1978-02-01 1983-10-19 The Wellcome Foundation Limited Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations thereof
DE2808086A1 (de) * 1978-02-24 1979-08-30 Bayer Ag Substituierte diphenyl-imidazolyl- methane, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2821829A1 (de) * 1978-05-19 1979-11-22 Basf Ag Mittel zur regulierung des pflanzenwachstums
JPS55313A (en) * 1978-06-13 1980-01-05 Kissei Pharmaceut Co Ltd Imidazole derivative
DE2847441A1 (de) * 1978-11-02 1980-05-22 Basf Ag Imidazol-kupferkomplexverbindungen
DK157860C (da) * 1979-06-07 1990-07-30 Shionogi & Co Analogifremgangsmaade til fremstilling af benzylimidazolderivater samt farmaceutisk acceptable syreadditionssalte deraf
US4281141A (en) * 1980-05-30 1981-07-28 Eli Lilly And Company 3-(Imidazol-4-yl)-2-phenylpropanenitriles
US4617307A (en) * 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4562199A (en) * 1983-08-11 1985-12-31 Thorogood Peter B Imidazole derivatives, compositions and use
EP0149976A3 (de) * 1983-12-30 1986-12-10 Ciba-Geigy Ag Substituierte Imidazole
US4801594A (en) * 1984-06-18 1989-01-31 Eli Lilly And Company Aromatase inhibitors
US4605661A (en) * 1984-06-18 1986-08-12 Eli Lilly And Company Aromastase inhibiting α,α-diarylimidazole-4(5)-propionitriles, α,α-diarylimidazole-4(5)-propionamides, and 4(5)-(2,2-diarylethyl)imidazoles
US4755526A (en) * 1984-06-18 1988-07-05 Eli Lilly And Company Method of inhibiting aromatase
US4766140A (en) * 1984-06-18 1988-08-23 Eli Lilly And Company Method of inhibiting aromatase
US4602025A (en) * 1984-06-18 1986-07-22 Eli Lilly And Company Aromatase inhibitors

Also Published As

Publication number Publication date
CS8707367A2 (en) 1991-02-12
HK50296A (en) 1996-03-29
NO170277B (no) 1992-06-22
PT84410A (en) 1987-04-01
SU1577695A3 (ru) 1990-07-07
EP0236940B1 (en) 1993-09-22
MTP998B (en) 1987-08-21
JPS62212369A (ja) 1987-09-18
NL970011I2 (nl) 1997-09-01
BG46598A3 (bg) 1990-01-15
NO170277C (no) 1992-09-30
MX5496A (es) 1993-12-01
LV5769B4 (lv) 1997-04-20
EP0236940A3 (en) 1989-10-18
HU202843B (en) 1991-04-29
HUT43822A (en) 1987-12-28
CZ279028B6 (en) 1994-11-16
SK279102B6 (sk) 1998-06-03
MC1805A1 (fr) 1987-12-22
PH24159A (en) 1990-03-22
EP0236940A2 (en) 1987-09-16
MY102428A (en) 1992-06-30
SK151287A3 (en) 1998-06-03
SU1549478A3 (ru) 1990-03-07
DK117687D0 (da) 1987-03-06
KR910000482B1 (ko) 1991-01-25
DE3787480T2 (de) 1994-02-24
US4749713A (en) 1988-06-07
DZ1055A1 (fr) 2004-09-13
RO101533B1 (en) 1992-06-25
DD264432A5 (de) 1989-02-01
TNSN87033A1 (fr) 1990-01-01
CY1905A (en) 1987-03-05
EP0236940B3 (en) 2011-03-23
CZ279027B6 (en) 1994-11-16
NO870937L (no) 1987-09-08
AU6976887A (en) 1987-09-10
LV5769A4 (lv) 1996-12-20
IL81746A0 (en) 1987-10-20
NO870937D0 (no) 1987-03-06
SU1470184A3 (ru) 1989-03-30
CS8701512A2 (en) 1991-02-12
PT84410B (pt) 1989-10-04
NL970011I1 (nl) 1997-05-01
BG61204B2 (bg) 1997-02-28
FI870903L (fi) 1987-09-08
DK172190B1 (da) 1997-12-22
DE3787480D1 (de) 1993-10-28
IE61101B1 (en) 1994-10-05
BG45701A3 (bg) 1989-07-14
SK279103B6 (sk) 1998-06-03
ZA871637B (en) 1987-10-28
SK736887A3 (en) 1998-06-03
SK736787A3 (en) 1998-06-03
PL151490B1 (en) 1990-09-28
RO101532B1 (en) 1992-11-03
ATE94873T1 (de) 1993-10-15
CZ279026B6 (en) 1994-11-16
SK279101B6 (sk) 1998-06-03
NO1998010I1 (no) 1998-03-04
PL152025B1 (en) 1990-10-31
FI870903A0 (fi) 1987-03-02
DK117687A (da) 1987-09-08
IL81746A (en) 1992-02-16
ES2059317T3 (es) 1994-11-16
KR870008851A (ko) 1987-10-21
CS8707368A2 (en) 1991-02-12
PL264460A1 (en) 1988-07-21
AU604011B2 (en) 1990-12-06
DE19775016I2 (de) 2002-02-21
JPH0755930B2 (ja) 1995-06-14
FI91857C (fi) 1994-08-25
FI91857B (fi) 1994-05-13
LU90128I2 (fr) 1997-10-06
IE870575L (en) 1987-09-07
MA20888A1 (fr) 1987-10-01
CA1316928C (en) 1993-04-27

Similar Documents

Publication Publication Date Title
BG45701A3 (bg) Метод за получаване на алфа-хетероциклично заместени толунитрили
ATE65994T1 (de) Insektentoetende pyrazoline.
FR2380266A1 (fr) Molybdates d'amines heterocycliques, procede d'obtention et application
DK142985A (da) Redox-indikatorer
BG30019A3 (bg) Метод за получаване на тризаместени 1-фенил-2,3,4,5-тетрахидро-1н- 3-бензазепини
BG45042A3 (bg) Метод за получаване на ацилирани дикетонови съединения
FI833918A0 (fi) -karboliner, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska preparat
BG28847A3 (bg) Метод за получаване на хидантоинови производни
BG32851A3 (bg) Метод за получаване на 3,4,5,6-тетрахидро-2н- -1-бензоксецини
BG29722A3 (bg) Метод за получаване на 2,5-дисубституирани пиримидин-4-они
BG40963A3 (bg) Метод за получаване на 1,3-дизаместени 2-оксиндоли
BG32268A3 (bg) Метод за получаване на имидазолови производни
BG28261A3 (bg) Метод за получаване на имидазолови производни
BG41124A3 (bg) Метод за получаване на бензамиди
BG36348A3 (bg) Метод за получаване на производни на тиенопиридинона
BG35039A3 (bg) Метод за получаване на заместени хетероциклични феноксиамини
AU539847B2 (en) 3,4,5-trihydroxypiperidine compounds
BG40147A3 (bg) Метод за получаване на хетероциклични съединения
DE3767287D1 (de) Potenzierung von prazosin.
BG32418A3 (bg) Метод за получаване на амидни производни на 1,2,3-тиадиазол -5-карбонова киселина
ATE69220T1 (de) Sechsgliedrige heterocyclische derivate von n'substituiertenn,n'-diacylhydrazinen.
BG38637A3 (bg) Метод за получаване на 2-екзо-хидрокси-7-оксабицикло 2,2,1 хептани
BG34610A3 (bg) Метод за получаване на 2',6'-диалкил -n-(алкоксиметил)-2-хлорацетанилиди
BG36935A3 (bg) Метод за получаване на бензодиазепинови съединения
BG35749A3 (bg) Метод за получаване на 20-дихидро-20,23-дидеокситидонолид